These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27563003)

  • 21. [Atherogenesis in human - clinical aspects of circulating immune complexes].
    Babintseva YD; Sergeeva AM; Karagodin VP; Orekhov AN
    Klin Med (Mosk); 2016; 94(5):325-32. PubMed ID: 30289642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Determination of malondialdehyde-modified LDL(MDA-LDL) and its potential usefulness].
    Kotani K; Kondo A; Manabe M; Maekawa M; Kanno T
    Rinsho Byori; 1997 Jan; 45(1):47-54. PubMed ID: 9022342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carbamyl adducts on low-density lipoprotein induce IgG response in LDLR-/- mice and bind plasma autoantibodies in humans under enhanced carbamylation.
    Kummu O; Turunen SP; Wang C; Lehtimäki J; Veneskoski M; Kastarinen H; Koivula MK; Risteli J; Kesäniemi YA; Hörkkö S
    Antioxid Redox Signal; 2013 Oct; 19(10):1047-62. PubMed ID: 23311771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation of MDA-LDL (malondialdehyde-modified low-density lipoprotein) as a prognostic marker for coronary artery disease in patients with type 2 diabetes mellitus.
    Kotani K; Tashiro J; Yamazaki K; Nakamura Y; Miyazaki A; Bujo H; Saito Y; Kanno T; Maekawa M
    Clin Chim Acta; 2015 Oct; 450():145-50. PubMed ID: 26265234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of capture assays for different modifications of human low-density lipoprotein.
    Virella G; Derrick MB; Pate V; Chassereau C; Thorpe SR; Lopes-Virella MF
    Clin Diagn Lab Immunol; 2005 Jan; 12(1):68-75. PubMed ID: 15642987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease.
    Boullier A; Hamon M; Walters-Laporte E; Martin-Nizart F; Mackereel R; Fruchart JC; Bertrand M; Duriez P
    Clin Chim Acta; 1995 Jun; 238(1):1-10. PubMed ID: 7554289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound.
    Tani S; Watanabe I; Anazawa T; Kawamata H; Tachibana E; Furukawa K; Sato Y; Nagao K; Kanmatsuse K; Kushiro T;
    Am J Cardiol; 2005 Oct; 96(8):1089-94. PubMed ID: 16214443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid composition of circulating multiple-modified low density lipoprotein.
    Zakiev ER; Sukhorukov VN; Melnichenko AA; Sobenin IA; Ivanova EA; Orekhov AN
    Lipids Health Dis; 2016 Aug; 15(1):134. PubMed ID: 27558696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carbohydrate composition of circulating multiple-modified low-density lipoprotein.
    Zakiev ER; Sobenin IA; Sukhorukov VN; Myasoedova VA; Ivanova EA; Orekhov AN
    Vasc Health Risk Manag; 2016; 12():379-385. PubMed ID: 27789955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension.
    Su J; Georgiades A; Wu R; Thulin T; de Faire U; Frostegård J
    Atherosclerosis; 2006 Sep; 188(1):160-6. PubMed ID: 16307748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Malondialdehyde-Modified Low-Density Lipoprotein on Tissue Characteristics in Patients With Stable Coronary Artery Disease　- Integrated Backscatter-Intravascular Ultrasound Study.
    Ikenaga H; Kurisu S; Kono S; Sumimoto Y; Watanabe N; Shimonaga T; Higaki T; Iwasaki T; Mitsuba N; Ishibashi K; Dohi Y; Fukuda Y; Kihara Y
    Circ J; 2016 Sep; 80(10):2173-82. PubMed ID: 27581176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody titer against malondialdehyde-modified LDL compares with HDL cholesterol concentration in identifying angiographically verified coronary artery disease. Comparison of tests by ROC analysis.
    Rontu R; Metso S; Jaakkola O; Nikkilä M; Jokela H; Lehtimäki T
    Clin Chem Lab Med; 2005; 43(4):357-60. PubMed ID: 15899649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.
    Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G
    J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent.
    Ito T; Fujita H; Tani T; Ohte N
    Atherosclerosis; 2015 Apr; 239(2):311-7. PubMed ID: 25682029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum.
    Kotani K; Maekawa M; Kanno T; Kondo A; Toda N; Manabe M
    Biochim Biophys Acta; 1994 Nov; 1215(1-2):121-5. PubMed ID: 7947993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women.
    Dotevall A; Hulthe J; Rosengren A; Wiklund O; Wilhelmsen L
    Clin Sci (Lond); 2001 Nov; 101(5):523-31. PubMed ID: 11672458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma levels of antibodies against oxidized LDL are inherited but not associated with HDL-cholesterol level in families with early coronary heart disease.
    Paavola T; Kangas-Kontio T; Salonurmi T; Kuusisto S; Huusko T; Savolainen MJ; Kakko S
    Atherosclerosis; 2012 Sep; 224(1):123-8. PubMed ID: 22818623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased autoantibodies against oxidized low-density lipoprotein in coronary circulation in patients with coronary spastic angina.
    Ogawa H; Soejima H; Takazoe K; Miyamoto S; Kajiwara I; Shimomura H; Sakamoto T; Yoshimura M; Kugiyama K; Kimura M; Yasue H
    Angiology; 2001 Mar; 52(3):167-74. PubMed ID: 11269779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease.
    Lourida ES; Papathanasiou AI; Goudevenos JA; Tselepis AD
    Prostaglandins Leukot Essent Fatty Acids; 2006 Aug; 75(2):117-26. PubMed ID: 16843649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes.
    Lopes-Virella MF; Hunt KJ; Baker NL; Virella G;
    J Diabetes Complications; 2016; 30(4):693-9. PubMed ID: 26861948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.